Screener
Amneal Pharmaceuticals, Inc. AMRX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s net income?
- Amneal Pharmaceuticals, Inc. (AMRX) reported net income of $57.66M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s net income changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s net income increased by 157.2% year-over-year, from $22.42M to $57.66M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s net income?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s net income has grown at a -34.4% compound annual growth rate (CAGR), from -$254.79M to $72.06M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Amneal Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude